Therefore, to further characterise these models at the baseline, we used RAD51 foci in tumour cells at the S-G2 phase of the cell cycle (geminin positive cells) by immunofluorescence (IF) to assess the HRR functionality. This evidence concerns the gene RAD51 and neoplasm.